Doctors map vision risks in lifesaving melanoma drugs
NCT ID NCT07427953
Summary
This study aimed to understand a specific eye side effect that can occur when melanoma patients take a common combination of targeted drugs (BRAF and MEK inhibitors). Researchers closely monitored the vision and eye health of 14 patients during and after their cancer treatment to see how their retinas were affected. The goal was to gather information to help doctors better recognize and manage this side effect in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
Conditions
Explore the condition pages connected to this study.